These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 15077278

  • 1. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, Pontikaki I.
    Arthritis Rheum; 2004 Apr 15; 51(2):301-2. PubMed ID: 15077278
    [No Abstract] [Full Text] [Related]

  • 2. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
    Sany J, Kaiser MJ.
    Ann Med Interne (Paris); 2002 Feb 15; 153(1):34-40. PubMed ID: 11994688
    [Abstract] [Full Text] [Related]

  • 3. [Etanercept].
    Mühlhäuser U, Münzel F, Eschenhagen T.
    Dtsch Med Wochenschr; 2003 Aug 22; 128(34-35):1775-8. PubMed ID: 12934172
    [No Abstract] [Full Text] [Related]

  • 4. Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky DS.
    N Engl J Med; 2000 Mar 16; 342(11):810-1. PubMed ID: 10717018
    [No Abstract] [Full Text] [Related]

  • 5. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
    Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, Cohen SB, Gangnon RE, Schiff MH.
    J Rheumatol; 2004 Jun 16; 31(6):1098-102. PubMed ID: 15170921
    [Abstract] [Full Text] [Related]

  • 6. [TNF-alpha inhibitors].
    Fain O.
    Rev Prat; 2003 Nov 30; 53(18):1989-90. PubMed ID: 15008210
    [No Abstract] [Full Text] [Related]

  • 7. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y, Coscojuela C, Vázquez C, Roselló R, Vera J.
    Br J Dermatol; 2007 Feb 30; 156(2):368-71. PubMed ID: 17223880
    [Abstract] [Full Text] [Related]

  • 8. Pulsating back pain associated with tumor necrosis factor-alpha blockade.
    Rozin AP, Braun-Moscovici Y, Balbir-Gurman A.
    Ann Pharmacother; 2008 Dec 30; 42(12):1912-3. PubMed ID: 19033477
    [No Abstract] [Full Text] [Related]

  • 9. [TNF inhibitors for treatment of rheumatoid arthritis].
    Otomo K, Koike T.
    Nihon Naika Gakkai Zasshi; 2008 Oct 10; 97(10):2405-12. PubMed ID: 19149036
    [No Abstract] [Full Text] [Related]

  • 10. Intraarticular injection of anti-tumor necrosis factor: Comment on the letter by Arnold et al.
    Bliddal H.
    Arthritis Rheum; 2004 Jun 10; 50(6):2037-8. PubMed ID: 15188385
    [No Abstract] [Full Text] [Related]

  • 11. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S, Prey S, Livideanu C, Jamard B, Lamant L, Cantagrel A, Paul C.
    J Eur Acad Dermatol Venereol; 2009 Aug 10; 23(8):967-8. PubMed ID: 19192017
    [No Abstract] [Full Text] [Related]

  • 12. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P.
    J Rheumatol; 2005 Nov 10; 32(11):2183-5. PubMed ID: 16265699
    [Abstract] [Full Text] [Related]

  • 13. Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis.
    Koens L, Senff NJ, Vermeer MH, Ronday HK, Willemze R, Jansen PM.
    Acta Derm Venereol; 2009 Nov 10; 89(6):653-4. PubMed ID: 19997706
    [No Abstract] [Full Text] [Related]

  • 14. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L, Mouthon L.
    J Rheumatol; 2004 Oct 10; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract] [Full Text] [Related]

  • 15. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.
    Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ.
    Br J Dermatol; 2004 Aug 10; 151(2):506-7. PubMed ID: 15327565
    [No Abstract] [Full Text] [Related]

  • 16. Prescribing antitumor necrosis factor drugs to patients with heart failure.
    Ziegelstein RC.
    Arch Intern Med; 2005 Jan 10; 165(1):118-9. PubMed ID: 15642887
    [No Abstract] [Full Text] [Related]

  • 17. Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
    Yildirim-Toruner C, Kimura Y, Rabinovich E.
    J Rheumatol; 2008 Aug 10; 35(8):1680-1. PubMed ID: 18671328
    [No Abstract] [Full Text] [Related]

  • 18. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
    Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, Allison J, Braun MM.
    Arthritis Rheum; 2007 Mar 15; 57(2):343-6. PubMed ID: 17330283
    [No Abstract] [Full Text] [Related]

  • 19. [Combination drug therapy in rheumatoid arthritis].
    Kawai S.
    Nihon Rinsho; 2005 Jan 15; 63 Suppl 1():549-55. PubMed ID: 15799416
    [No Abstract] [Full Text] [Related]

  • 20. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J, Welte T, Kellner U, Pap T.
    Arthritis Rheum; 2002 Mar 15; 46(3):843-4. PubMed ID: 11920425
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.